Session Abstract – PMWC 2026 Silicon Valley
Track Chair: Burns Blaxall, Aranscia
- TBA
Speaker Profile
Ph.D., Director, Research Services, Zymo
Biography
Keith Booher has been involved in the biotech sector for 15 years taking on various scientific, business development, and leadership roles. In his current position at Zymo Research, Keith leads the professional research services team, which primarily utilizes NGS technology to answer questions in the field of genomics especially, microbiome, epigenome, and transcriptome focused analysis. In addition, Keith is the Principal Investigator on over $12 million in research grants and contracts from various federal and local entities. Keith is particularly interested in multi-omics approaches that utilize advanced sample prep, cutting edge sequencing, and Artificial Intelligence or Machine Learning tools to help solve the most challenging problems in molecular biology.
AI and Data Sciences Showcase:
Zymo
Zymo Research, a privately owned biotech company founded in 1994, is a global leader in molecular tools for life sciences. Driven by the principle "The Beauty of Science is to Make Things Simple," Zymo is dedicated to developing innovative solutions that address complex scientific challenges.
Speaker Profile
Head of Products & Platform (BioStrand), IPA
Biography
Arnout Van Hyftes journey with BioStrand, now a subsidiary of IPA (ImmunoPrecise Antibodies), began in 2019 as a key member of the founding team. He has played a pivotal role in shaping the company's commercial strategies, setting the stage for its remarkable growth, and building a robust infrastructure that forms the very foundation of BioStrand's operations. Arnout oversees the development team, ensuring their seamless coordination and fostering a culture of innovation. His leadership extends to crafting effective sales and marketing strategies, as well as engaging with the market to cultivate meaningful relationships.
AI and Data Sciences Showcase:
ImmunoPrecise (IPA)
ImmunoPrecise is a biotherapeutic research hub leveraging systems biology, multiomics modeling and complex artificial intelligence systems to support its proprietary antibody discovery technologies. Combining an AI driven approach with best-in-class laboratory capabilities creates a powerful synergy that is revolutionizing antibody discovery.
